Incyte's Trading Volume Surges 84% to 2.30 Billion, Ranks 431st in Market as it Partners with Qiagen for MPN Diagnostic Panel

On June 16, 2025, Incyte's trading volume reached 2.30 billion, marking an 84.13% increase from the previous day, placing it 431st in the day's stock market rankings. Incyte's stock price rose by 5.12%.

Incyte has entered into a master collaboration agreement with Qiagen to develop a diagnostic panel aimed at aiding the treatment of individuals with myeloproliferative neoplasms (MPNs), a group of rare blood cancers. This partnership is focused on supporting Incyte's investigational therapies, including the monoclonal antibody INCA033989, which targets mutant calreticulin (mutCALR) in conditions such as myelofibrosis (MF) and essential thrombocythemia (ET).

Qiagen will create a multimodal panel using next-generation sequencing (NGS) to detect clinically relevant gene alterations in hematological malignancies. The validation of the panel will be conducted using the Illumina NextSeq 550Dx platform. Regulatory submissions and market access activities will be supported by Qiagen across the European Union, the US, and the Asia-Pacific regions.

Incyte's research and development head and president, Pablo Cagnoni, expressed excitement about the partnership, stating that it will facilitate CALR testing for patients with MPNs on a global basis. The development of companion diagnostics for mutCALR, coupled with the potential for new medicines to selectively target disease-initiating cells, is seen as a critical step toward changing the course of disease in patients with ET and MF. Incyte's INCA033989 for mutCALR ET or MF aims to eliminate malignant cells while sparing healthy ones. CALR plays a crucial role in managing calcium levels within cells and ensuring the production of proteins.